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Comorbidity of migraine with ADHD in
adults
Thomas Folkmann Hansen1,2,13*, Louise K. Hoeffding3, Lisette Kogelman1, Thilde Marie Haspang1, Henrik Ullum3,
Erik Sørensen3, Christian Erikstrup4, Ole Birger Pedersen5, Kaspar René Nielsen6, Henrik Hjalgrim7,8,
Helene M. Paarup9, Thomas Werge10,11,12 and Kristoffer Burgdorf3
Abstract
Background: Migraine and Attention Deficit and Hyperactivity Disorder (ADHD) have been found to be associated
in child and adolescent cohorts; however, the association has not been assessed in adults or otherwise healthy
population. Assessing the comorbidity between ADHD and migraine may clarify the etiopathology of both diseases.
Thus, the objective is to assess whether migraine (with and without visual disturbances) and ADHD are comorbid
disorders.
Methods: Participants from the Danish Blood Donor Study (N = 26,456, age 18–65, 46% female) were assessed for
migraine and ADHD using the ASRS ver 1.1 clinically validated questionnaire and self-reported migraine in a cross-
sectional study. Logistic regression was used to examine the comorbidity between migraine and ADHD, and their
associated endophenotypes.
Results: Migraine was strongly associated with ADHD (OR = 1.8, 95% CI = 1.5–2.1), (238/6152 vs 690/19,376). There
was a significant interaction between age and gender, with comorbidity increasing with age and female sex. Post-
hoc analysis showed that migraine with visual disturbance was generally associated with a marginally higher risk of
ADHD and this was independent of ADHD endophenotypes.
Conclusion: Migraine and ADHD were demonstrated to be comorbid disorders; the association with ADHD was
most prominent for participants with migraine with visual disturbances. Future studies will elucidate which genetic
and environmental factors contribute to migraine-ADHD comorbidity.
Keywords: Migraine, Attention deficiency and hyperactivity disorder, Comorbidity
Background
Migraine is a complex and multifactorial headache disorder
with a lifetime prevalence of 16–18% [1–3]. Migraine is
twice as prevalent in females, and onset is typically between
adolescence and the late 50s [1–3]. According to the World
Health Organization (WHO), migraine is the sixth most
disabling disease in the world with high financial costs to
society [4]. Response to acute treatment varies considerably
and approximately 20% of the pharmacologically treated
patients experience no symptom relief after medication [5].
There are two major endophenotypes in migraine: migraine
with or without aura. Aura is a sensory disturbance, which
is predominantly seen as visual disturbances (99%) with a
subsequent headache or migraine [6, 7].
Attention deficit and hyperactivity disorder (ADHD) is
characterized by inappropriate levels of inattention, e.g.,
difficulty keeping attention, keeping track of details, and
difficulty structuring trivial duties or following instructions,
hyperactivity, e.g., speaks a lot, difficulty relaxing or sitting
still, and impulsivity, e.g., often interrupts other people dur-
ing conversations or answers a question before the question
is finished [8]. In contrast to migraine, ADHD has an early
onset and a pooled worldwide prevalence of 5.3% in child
and adolescent populations [9]. The current treatment
strategies do not completely remove the symptoms in both
children and adults and approximately 30% of all patients
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do not respond to medical treatment or develop serious
adverse reactions [10, 11].
It is well established that migraine is comorbid with
psychiatric traits, in particular depressive and bipolar
disorder [12, 13], and that the comorbidity is partly
explained by shared genetics [14]. More recently, the
comorbidity between migraine and ADHD has also
been assessed [15–18]. In adults, a clinical case-control
study of ADHD (n = 572/675) found an increased preva-
lence of migraine when compared to community controls
[16], and subsequently the same investigators showed a
positive association between prescription of anti-migraine
and anti-ADHD drugs to adults in the total Norwegian
population(n > 4mill) [17]. In line with this, Arruda et al.
reported a higher prevalence of ADHD among children
with migraine (5–12 years) than for non-headache individ-
uals in a pediatric population cohort (n = 5671) [19]. Ac-
cording to the recently published meta-analysis including
child and adolescence studies and the Fasmer et al. adult
study, there is a positive association between migraine and
ADHD with odds-ratio of 1.3 [16, 20].
Using a cross-sectional study of adults (age 18–65 years),
we test the hypothesis that migraine is comorbid with
ADHD in 26,456 participants using clinically validated
questionnaires.
Methods
Participants
From November 2015 to September 2017 voluntary blood
donors were recruited as part of the Danish Blood Donor
Study (DBDS) (www.DBDS.dk). In brief, the DBDS was
initiated in 2010 and is an ongoing prospective research
cohort and biobank that recruits participants between 17
and 67 years of age from blood banks across Denmark
[21, 22]. Individuals in chronic medical treatment or
frequent travelers to countries considered resulting in
high-risk of blood disease are not allowed to partici-
pate. Approximately 95% of all invited individuals are
consented to participate in DBDS [22]. At enrolment,
each individual gives oral and written informed consent
to participate in DBDS and subsequently answers a
digital tablet-based questionnaire including a migraine
(two questions) and an ADHD (18 questions) module.
In total, 29,489 participants were recruited to the study.
The study is approved by the Danish Data Protection
Agency (2007–58-0015) and the Ethical Committee of
Central Denmark (M-20090237). For further details about
the DBDS platform and questionnaire, see Pedersen et al.
[22] or Burgdorf et al. [21]
In total, 29,489 participants were given a questionnaire.
We excluded 3033 individuals due to missing answers on
either the SQM (n = 2057) or the ASRS items (n = 1108) of
which n = 132 were missing both. The excluded individuals
did not differ significantly with respect to age (chi-square
test, P-value = 0.24) compared to the study population.
The excluded individuals were slightly older (median
age: 44 years, IQR = 31–54 years) when compared to
the study population (median age: 42 years, IQR = 30–
52 years) (Wilcoxon test, P-value = 3.7e-8). Importantly,
the frequency of migraine in individuals excluded because
of missing information in the ASRS questionnaire was
similar to that of the study population (24.1%). Further,
the frequency of ADHD in individuals excluded because
of missing items in the SQM questionnaire was similar to
that of the study population 4.2%.
The migraine module
The presence of migraine was evaluated by two questions
from the population screening questionnaire for migraine
(SQM). The participants were asked two questions (“Have
you ever had migraine?” and “Have you ever had visual
disturbances lasting 5-60 min followed by headache?”) of
the original SQM. Participants who had a positive re-
sponse to either of the two questions were considered to
have migraine and are referred as migraine cases in this
study. Individuals with missing information or who an-
swered “I don’t know” were excluded. A detailed descrip-
tion of the SQM questionnaire can be found elsewhere
[23]. In short, the SQM has previously been shown to
identify 93% of those with migraine with aura and 75% of
those with migraine without aura in a Danish setting [23].
Using the national prescription register, we found that
89.5% of those prescribed migraine-specific treatment, i.e.
triptans ATC-codes N02CC01–7, are captured using these
two questions.
The ADHD module
Current self-reported ADHD symptoms were assessed
using the current national recommendation for clinical
assessment of adults by using the ADHD Self-Report Scale
v1.1 (ASRS) [24, 25] translated to Danish Dalsgaard et al.
[26]. The ASRS consists of 18 items based on the Diagnos-
tic and Statistical Manual of Mental Disorders fourth edi-
tion (DSM-IV) diagnostic criteria for ADHD and is the
recommended version for clinical use in Denmark. Each
of the 18 questions was scored on a five-point Likert scale
ranging from never = 0 to very often = 4. In this study we
use the optimal Kessler et al. 18-item ASRS scale score
obtained by summarizing all items (total range of 0–72) as
the primary outcome. The ASRS has been validated in
multiple countries using different populations [27–30].
The scale dichotomizes ADHD based upon all items for
ADHD (having a score > 36), inattentive subtype (items
1–4 + 7–11, having a score > 23), the hyperactivity-impul-
sivity subtype (items 5–6 + 12–18, having a score > 23),
and the 6-item screening score (having a score > 13) [28].
A more detailed description of the ASRS questionnaire
can be found elsewhere [24].
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Statistical analysis
The study population was described by numbers and per-
centages for categorical variables and as median and inter-
quartile range (IQR) for continuous variables. Differences
in distributions between participants with and without mi-
graine and ADHD symptoms were analyzed using Fisher’s
exact test or Mann-Whitney/Wilcoxon test (age does not
follow a normal distribution, thus non-parametric analysis
is used).
Logistic regression was used to analyze the association
between migraine and ADHD (dichotomous variables)
in the study population, adjusting for age, sex, and the
interaction between sex and age, with migraine as the
dependent variable. We used a logistic regression model
with a binary outcome of either migraine, migraine with
visual disturbance, or migraine without visual disturbances.
We did not include sampling weights, as these are not
available for DBDS. We calculatedthe regression in two
ways including age as a quantitative trait or as a categorical
trait (10 year interval). We report the derived odds ratios
(OR) and 95% confidence intervals (CIs). A P-value< 0.05
was considered statistically significant. Post-hoc analyses
were performed using different thresholds of the ASRS
score (from 0 and 52), and single ASRS items (data not
shown). To check if the specified model is appropriate
for the data, the predicted and observed residuals were
inspected for each analysis and no issues were observed.
All statistical analyses were performed using the statis-
tical package for R version 3.3.3: stat, basic, ggplot2, eep-
tools, cowplot, and GirdExtra.
Results
Study population
The population consisted of 26,456 participants (median
age: 42 years, IQR = 30–52 years) from the DBDS, of
whom 24.2% screened positive for migraine (median age:
42 years, IQR = 31–51 years, female-to-male ratio: 1:0.6),
2.61% screened positive for ADHD (median age: 29 years,
IQR = 25–40 years, female-to-male ratio: 1:1.4), and
0.90% reported having both migraine and ADHD (me-
dian age: 31 years, IQR = 24–41 years, male-to-female
ratio: 1:0.74), see Table 1 for the prevalence. There was a
significant difference in the age and sex distributions for
participants with either migraine or ADHD (Wilcoxon
test and chi-square exact, P < 1e-15 and P < 1e-15, re-
spectively) (Fig. 1), thus we included a correction for
age, sex and interaction of age and sex in the model.
There was an association between migraine and ADHD
symptoms with OR = 1.81 (95CI%: 1.53–2.12, P = 1.4e-14)
including corrections for age, sex and the interaction of
age and sex as covariates (Table 2a). As expected, male
sex is protective (OR = 0.57), and increased age further in-
creased protection with OR = 9.99 per year (Table 2a). To
ease literature comparison, we present the sex-stratified
results (Table 2b + c) and repeated the regression analysis
using age bins (10 years), see Table 3. The association was
not explained by one specific item in the ASRS question-
naire (data not shown). The highest risk was found for mi-
graine with visual disturbances and ADHD symptoms
(OR = 2.05, 95CI%: 1.55–2.68, P = 3.3e-11). Using the na-
tional prescription register we did not find any difference
in frequency of triptan purchases with and without ADHD
symptoms (at least one purchase: 22.1% vs 23.2%, p = 0.80,
at least 2 purchases: 13.7% vs 14.4%, and at least 10 pur-
chases: 3.2% vs 4.9%, p = 0.39).
The association between migraine and ADHD symptoms
was statistically significant irrespective of the employed
ASRS score threshold (Fig. 2a), with a tendency to increase
with the ASRS score. The same results were observed for
ADHD symptoms and migraine with visual disturbances
(Fig. 2b), however; no association was detected for migraine
without visual disturbances with ASRS scores below 10 and
above 51 (Fig. 2c).
Migraine was associated with both ADHD endopheno-
types (inattention and hyperactivity-impulsivity), with
migraine with visual disturbances showing a marginally
Table 1 Characteristics of the study population (N = 26,456) with respect to migraine and ADHD symptoms
N
Description Female (%e) Male Total (%f) P-valued
The total study population 12,247 (46.3) 14,209 26,456 (100)
Migrainea 4024 (63.0) 2366 6390 (24.2) < 0.001
- Without visual disturbances 2187 (62.0) 1343 3530 (13.3) < 0.001
- With visual disturbances 1832 (64.2) 1019 2851 (10.8) < 0.001
ADHDb 285 (41.3) 405 690 (2.6) 0.0085
- Inattention 83 (39.7) 126 209 (0.79) 0.06
- Hyperactivity-impulsivity 67 (43.0) 89 156 (0.59) 0.42
- Screening itemsc 182 (26.7) 400 682 (2.58) < 0.001
Migraine and ADHD 137 (57.6) 101 238 (0.90) < 0.001
aSymptoms of migraine was assessed by the SQM [19],b ADHD symptoms were assessed by the ASRS [20], c Screening as described by Kessing et al. [23], d Test of
gender differences of total population and subgroup by chi-square test, e percentage females of the subgrup, f percentage of the total sample
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Fig. 1 Age distribution. The X-axis shows age from 17 to 66 years, the Y-axis shows the proportional distribution by age of the study population,
colored according to phenotype status on the right
Table 2 Multivariable Logistic regression analysis
Model a) All genders b) Females only c) Males only
Outcome Variable OR CI 95% P-value OR CI 95% P-value OR CI 95% P-value
Migraine ADHD 1.81 1.53–2.12 < 0.001 2.01 1.58–2.54 < 0.001 1.64 1.30–2.06 < 0.001
Age 1.00 1.00–1.01 0.001 1.01 1.00–1.01 < 0.001 1.00 0.99–1.00 0.051
Gender (Male) 0.57 0.47–0.69 < 0.001
Age:Gender (Male) 0.99 0.99–0.99 < 0.001
With Visual Disturbances ADHD 1.98 1.61–2.41 < 0.001 2.05 1.55–2.68 < 0.001 1.89 1.38–2.53 < 0.001
Age 1.00 1.00–1.00 0.84 1.00 1.00–1.00 0.11 1.00 0.99–1.00 0.11
Gender (Male) 0.53 0.40–0.69 < 0.001
Age:Gender (Male) 1.00 0.99–1.00 0.16
Without Visual Disturbances ADHD 1.52 1.22–1.88 < 0.001 1.69 1.24–2.27 < 0.001 1.37 0.99–1.86 0.047
Age 1.01 1.00–1.01 < 0.001 1.01 1.00–1.01 < 0.001 1.00 0.99–1.00 0.23
Gender (Male) 0.63 0.49–0.82 < 0.001
Age:Gender (Male) 0.99 0.98–1.00 < 0.001
Multivariable Logistic regression analysis of migraine and migraine with and without visual disturbances, subsequent stratified on gender.
Reference of the regression model is given in ()
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larger effect than migraine without visual disturbances,
notably with overlapping confidence intervals (Fig. 3).
Discussion
We address the comorbidity of migraine and ADHD
symptoms in a healthy population of 29,489 adults using
two clinically validated questionnaires (SQM and ASRS).
Our results show a strong and statistically significant
comorbidity between the two disorders which was irre-
spective of the threshold (i.e., not restricted to the com-
monly used ASRS score threshold of 37 (Fig. 2). The
regression model clearly shows that being male protects
against migraine and increased age is further protective
as seen in the interaction between age and sex (Table 2).
Stratified analyses suggested that the observed comorbid-
ity was more pronounced in migraineurs experiencing vis-
ual disturbances; however, no differences in association
with migraine were seen for the two ADHD endopheno-
types (inattention and hyperactivity-impulsivity).
The current study significantly supplements the sparse
literature regarding the comorbidity between migraine and
ADHD in adults by using a large, healthy study population
of individuals who have not been exposed to chronic treat-
ment for migraine or for ADHD. It supports the meta-ana-
lysis by Salem et al., showing OR of 1.3, consisting
primarily of child and adolescence studies. This
meta-analysis cohort consisted of a clinical case-control co-
hort, (n = 572) with ADHD [16], and a cross-sectional study
using prescription data on anti-migraine and anti-ADHD
drugs from the entire Norwegian population [17]. Thus,
the comorbidity between migraine and ADHD seems
present both in and out of a clinical setting. The origin of
the comorbidity is not obvious and typical prognostic fea-
tures such as the age of onset, and the female-to-male ratio
of the two diseases are somewhat contradicting. It has pre-
viously been suggested that the co-occurrence of migraine
and ADHD originates from common pathophysiological
mechanisms potentially related to dysfunctions in the dopa-
minergic system [16, 17, 31]. This arises because many of
the migraine symptoms, including prodromal symptoms,
can be provoked with dopamine receptor stimulation, and
some can even be quantified in rat models with dopamin-
ergic activiation [31]. Dopamine has long been thought to
be involved in ADHD pathology, and the effective ADHD
drug, methylphenidate, acts by inhibiting dopamine re-
uptake. However, the comorbidity could also be more com-
plex because of common co-morbidities of other
psychiatric disorders such as anxiety and mood disorders
[13, 32–36]. Their etiological comorbidity may arise be-
cause of pleiotropic factors. This has recently been sup-
ported by Antilla et al., showing a significant genetic
correlation between migraine and ADHD [37]. Interest-
ingly, major depressive disorder was also found to signifi-
cantly correlate with both migraine and ADHD suggesting
that common pleiotropic factors exist.
The observed prevalence of migraine and ADHD (34.7%)
was higher than reported by Fasmer et al. (28.3%) in a sam-
ple of ADHD patients with similar age and sex distribution
[16]. However, there is an anecdote among headache indi-
viduals with headache that donating blood gives symptom
relief, which could explain the frequency of migraine, i.e.
bloodletting by phlebotomy. Furthermore, we used self-re-
ported ADHD rather than formal clinical diagnoses in
our analysis, which may influence the results with false
positive and negative cases. Despite these methodological
Table 3 Multivariable logistic regression analysis
Outcome Variable OR CI 95% P-value
Migraine ADHD 1,86 1,58-2,19 < 0.001
Age 3Xa 1,34 1,20-1,51 < 0.001
Age 4Xa 1,59 1,43-1,76 < 0.001
Age 5Xa 1,27 1,14-1,42 < 0.001
Age 60 + a 0,98 0,84-1,15 0.80
Gender (Male) 0,49 0,44-0,56 < 0.001
Gender (Male) interaction with:
Age 3Xa 0,78 0,66-0,93 0.007
Age 4Xa 0,75 0,63-0,88 < 0.001
Age 5Xa 0,75 0,63-0,89 0.0013
Age 60 + a 0,84 0,66-1,07 0.16
With Visual Disturbances ADHD 2,01 1,63-2,45 < 0.001
Age 3Xa 1,13 0,97-1,31 0.110
Age 4Xa 1,20 1,05-1,38 0.0095
Age 5Xa 1,13 0,98-1,31 0.090
Age 60 + a 0,78 0,63-0,97 0.028
Gender (Male) 0,49 0,41-0,57 < 0.001
Gender (Male) interaction with:
Age 3Xa 0,90 0,71-1,15 0.41
Age 4Xa 0,83 0,66-1,05 0.13
Age 5Xa 0,79 0,62-1,01 0.06
Age 60 + a 1,12 0,80-1,57 0.5
Without Visual Disturbances ADHD 1,59 1,28-1,97 < 0.001
Age 3Xa 1,47 1,27-1,70 < 0.001
Age 4Xa 1,81 1,59-2,07 < 0.001
Age 5Xa 1,34 1,16-1,54 < 0.001
Age 60 + a 1,15 0,94-1,39 0.16
Gender (Male) 0,53 0,46-0,63 < 0.001
Gender (Male) interaction with:
Age 3Xa 0,73 0,58-0,92 0.0069
Age 4Xa 0,72 0,59-0,89 0.0026
Age 5Xa 0,75 0,60-0,93 0.011
Age 60 + a 0,69 0,50-0,94 0.021
a Reference is age < 30
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differences, we found the prevalence of self-reported mi-
graine and ADHD symptoms in males (24% vs. 23%) to be
like that reported by Fasmer et al. [16].
We found that the comorbidity between migraine and
ADHD was most prevalent among participants peaking
at 52 to 53 years of age, and in the 40 decade compared
to the 17–29 age group, which is somewhat inversely
correlated with the age distribution of ADHD symptoms
in the study population (Fig. 1). This could imply that
the manifestations of comorbid migraine and ADHD
occur rather late in life when compared to ADHD in gen-
eral, or that ADHD symptoms mask the presence of mi-
graine in the younger participants. Similar results have
been reported by Fasmer et al. [17] using simultaneous
Fig. 2 The odds ratio of the multivariable regression analysis at each ASRS score. X-axis presents the ASRS score. The vertical red dotted line
marks the threshold for ADHD for the optimal 18-item score. Left Y-axis is the Odds Ratio indicated as the black line and the 95% confidence
interval by the grey area. All analysis is done with multivariable logistic regression adjusting for age, sex and the interaction of age and sex
Fig. 3 Analysis of ADHD and Migraine endophenotypes. X-axes are odds ratio (black dot) and 95% confidence intervals (black lines) with a grey
vertical line indicating an odds ratio of 1. The three graphs display migraine, and migraine with and without visual disturbances. The Y-axis
displays the ADHD and two ADHD endophenotypes
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prescriptions of anti-migraine and anti-ADHD medication
as a proxy for comorbidity. However, this was not true for
the 10–19 years age group, suggesting that ADHD among
adolescents may have no comorbidity with migraine
and thus having a distinct etiopathology or, as previ-
ously mentioned, there is a masking of migraine symp-
toms in young individuals with ADHD. The notion of a
different etiopathology among ADHD patients is suggested
by Johansson et al. (Johansson et al. 2008), showing that
susceptibility genes differ between persistent and juvenile
ADHD [38]. Furthermore, the transition of ADHD symp-
toms from childhood to adulthood is well recognized where
the hyperactivity-impulsivity often becomes less prominent.
We did not detect a specific association between any
ADHD endophenotypes and migraine which is congruent
with previous reports for children, e.g., Pakainis et al. and
Arruda et al [19, 39] It is noteworthy that we do not see a
large difference between ADHD inattention and hyper-
active endophenotype. Although speculative, the smaller
difference between hyperactive and inattention endophe-
notype in the study cohort could reflect that the inatten-
tion is more often referred to treatment and thus are not
permitted to donate blood [40].
Participants reporting migraine preceded by visual distur-
bances (migraine with visual aura symptoms) were more
often affected by co-occurring ADHD symptoms when
compared to participants reporting no visual disturbances
and combined (Table 2, Fig. 2). No obvious shared mechan-
ism between visual disturbances and ADHD symptoms is
known. The neurovascular phenomenon cortical depres-
sion spreading is suggested as the pathophysiology of aura
symptoms in migraine patients [41], however, there are no
published studies on ADHD patients. Ophthalmologic dis-
turbances appear to be more frequent in patients diagnosed
with ADHD [42], however, it is very speculative whether
this could explain the observed comorbidity and further
studies are needed.
The strength of the study is the large sample size and
that chronic treatment of migraine and ADHD do not
influence the results, e.g., treatment-induced migraine
attacks. Furthermore, we used validated questionnaires
to assess migraine and ADHD symptoms. In accordance
with Danish clinical guides we use the recommended
version of ASRS to assess ADHD. While a new version
based on DSM V exists, a recent study found almost
identical specificity and sensitivity of the two versions
[43]. Furthermore, we show that 89% of individuals using
triptans are captured, and the prevalence of triptan users
in migraineurs with and without ADHD symptoms is the
same. When interpreting the results, it is important to
take into consideration that the study population is a
healthy donor population, presumably producing a con-
servative estimate of the association as individuals exposed
to chronic medication or chronic illness are excluded as
donors. Further, we suggest carrying out longitudinal co-
hort and twin studies to assess causality.
Conclusion
We demonstrate a significant corbobidity between migraine
and ADHD in adults, and this is most prominent for partic-
ipants with migraine with visual disturbances. These results
contribute to the understanding of genetic correlation seen
between ADHD and migraine and seeds future studies that
will elucidate which genetic and environmental factors con-
tribute to migraine-ADHD comorbidity.
Article highlights
 This study examined the association between
migraine and ADHD in a large adult population
 There is a strong association between migraine and
ADHD (odds ratio = 1.8, 95% CI = 1.5–2.1)
 The association between migraine and ADHD seems
strongest for individuals with visual disturbances
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